DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grace, J. M.
Right arrow Articles by Brewer, T. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grace, J. M.
Right arrow Articles by Brewer, T. G.

Vol. 26, Issue 4, 313-317, April 1998

Metabolism of beta -Arteether to Dihydroqinghaosu by Human Liver Microsomes and Recombinant Cytochrome P450

James M. Grace, Antonio J. Aguilar, Kimberly M. Trotman, and Thomas G. Brewer

Walter Reed Army Institute of Research, Department of Pharmacology, and Armed Forces Research Institute of Medical Sciences

beta -Arteether (AE) is an endoperoxide sesquiterpene lactone derivative currently being developed for the treatment of severe, complicated malaria caused by multidrug-resistant Plasmodium falciparum. Studies were undertaken to determine which form(s) of human cytochrome P-450 catalyze the conversion of beta -arteether to its deethylated metabolite, dihydroqinghaosu (DQHS), itself a potent antimalarial compound. In human liver microsomes, AE was metabolized to DQHS with a Km of 53.7 ± 29.5 µM and a Vmax of 1.64 ± 1.78 nmol DQHS/min/mg protein. AE biotransformation to DQHS was inhibited by ketoconazole and troleandomycin. Ketoconazole was a competitive inhibitor, with an apparent Ki of 0.33 ± 0.11 µM. Because AE is being developed for patients who fail primary treatment, it is possible that AE may be involved in life-threatening drug-drug interactions, such as the associated cardiotoxicity of mefloquine and quinidine. Coincubation of AE with other antimalarials showed mefloquine and quinidine to be competitive inhibitors with a mean Ki of 41 and 111 µM, respectively.

Metabolism of AE using human recombinant P450s provided evidence that cytochrome P450s 2B6, 3A4, and 3A5 were the primary isozymes responsible for its deethylation. CYP3A4 metabolized AE to dihydroqinghaosu at a rate approximately 10 times that of CYP2B6 and ~4.5-fold greater than that of CYP3A5. These results demonstrate that CYP3A4 is the primary isozyme involved in the metabolism of AE to its active metabolite, DQHS, with secondary contributions by CYP2B6 and -3A5.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
P. Agnamey, P. Brasseur, P. E. de Pecoulas, M. Vaillant, and P. Olliaro
Plasmodium falciparum In Vitro Susceptibility to Antimalarial Drugs in Casamance (Southwestern Senegal) during the First 5 Years of Routine Use of Artesunate-Amodiaquine.
Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1531 - 1534.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Ekins, S. Andreyev, A. Ryabov, E. Kirillov, E. A. Rakhmatulin, S. Sorokina, A. Bugrim, and T. Nikolskaya
A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT
Drug Metab. Dispos., March 1, 2006; 34(3): 495 - 503.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
D. MENARD, M. D. MATSIKA-CLAQUIN, D. DJALLE, F. YAPOU, A. MANIRAKIZA, V. DOLMAZON, J. SARDA, and A. TALARMIN
ASSOCIATION OF FAILURES OF SEVEN-DAY COURSES OF ARTESUNATE IN A NON-IMMUNE POPULATION IN BANGUI, CENTRAL AFRICAN REPUBLIC WITH DECREASED SENSITIVITY OF PLASMODIUM FALCIPARUM
Am J Trop Med Hyg, September 1, 2005; 73(3): 616 - 621.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. T. Hien, T. M. E. Davis, L. V. Chuong, K. F. Ilett, D. X. T. Sinh, N. H. Phu, C. Agus, G. M. Chiswell, N. J. White, and J. Farrar
Comparative Pharmacokinetics of Intramuscular Artesunate and Artemether in Patients with Severe Falciparum Malaria
Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4234 - 4239.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Q. Wang and J. R. Halpert
Combined Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Cytochrome P450 2B6 Substrates and Protein Homology Modeling
Drug Metab. Dispos., January 1, 2002; 30(1): 86 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. L. Maggs, L. P. D. Bishop, G. Edwards, P. M. O'Neill, S. A. Ward, P. A. Winstanley, and B. K. Park
Biliary Metabolites of beta -Artemether in Rats: Biotransformations of an Antimalarial Endoperoxide
Drug Metab. Dispos., February 1, 2000; 28(2): 209 - 217.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Ekins, G. Bravi, B. J. Ring, T. A. Gillespie, J. S. Gillespie, M. Vandenbranden, S. A. Wrighton, and J. H. Wikel
Three-Dimensional Quantitative Structure Activity Relationship Analyses of Substrates for CYP2B6
J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 21 - 29.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.